Clinical trial readout dates for Gilead Sciences Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 2 Lenacapavir Injection Pre-Exposure Prophylaxis of HIV Infection · NCT06101342 | July 2026 Primary data collected |
| Phase 2 Lenacapavir Tablet Pre-Exposure Prophylaxis of HIV Infection · NCT06101329 | July 2026 Primary data collected |
| Phase 2 Lenacapavir Injection Pre-Exposure Prophylaxis of HIV Infection · NCT06513312 | May 2026 Primary data collected |
| Phase 3 Sacituzumab Govitecan-hziy Metastatic Breast Cancer · NCT04639986 | December 2026 Ongoing |
| Phase 2 Tilpisertib Fosmecarbil Ulcerative Colitis · NCT06029972 | January 2027 Ongoing |
| Phase 3 Sacituzumab Govitecan-hziy Triple Negative Breast Cancer; PD-L1 Positive · NCT05382286 | February 2027 Ongoing |
| Phase 2 Oral Lenacapavir HIV-1-infection · NCT06749054 | March 2027 Recruiting |
| Phase 2 Sacituzumab Govitecan-hziy (SG) Non-small Cell Lung Cancer · NCT05186974 | March 2027 Ongoing |
| Phase 2 Domvanalimab Head and Neck Squamous Cell Carcinoma · NCT06727565 | March 2027 Ongoing |
| Phase 1/2 Sacituzumab Govitecan-hziy Advanced Solid Tumor; Metastatic Triple-Negative Breast Cancer · NCT05101096 | May 2027 Ongoing |
| Phase 3 Sacituzumab govitecan-hziy (SG) Triple Negative Breast Cancer · NCT05633654 | June 2027 Recruiting |
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-10-29 |